The company's strategy combines a pan-RAS molecular glue and a pan-KRAS inhibitor, giving exposure to different "swim lanes" that could emerge across tumor types and treatment settings. With a strong cash position of $411 million as of March 31, 2025, the company has operational funding through the second half of 2028. In January 2026, Erasca completed an upsized public offering of 25,875,000 shares, raising $225 million, further strengthening its financial runway.
Cyborg Score Rationale
Early clinical data shows encouraging efficacy signals across multiple tumor types, with confirmed partial responses at low doses and favorable safety profiles with no dose-limiting toxicities. ERAS-0015 demonstrates 8-21 fold higher binding affinity than competitors, requiring roughly 1/10 to 1/5 of the dose to achieve comparable tumor regression. However, the company is still clinical-stage with significant execution risk ahead.
Top Insights
Dose escalation in the Phase I AURORAS-1 study of ERAS-0015 is progressing faster than anticipated, with enrollment momentum supporting rapid advancement through multiple dose levels.
Erasca raised $225 million in January 2026 through an upsized public offering, demonstrating strong investor confidence in its RAS-targeted pipeline.
The FDA cleared an IND for ERAS-0015 and Erasca submitted an IND for ERAS-4001, with initial monotherapy data expected in 2026.
The U.S. Patent Office issued Patent No. 12,458,647 for ERAS-0015, providing protection until September 2043.
Named Competitors
RMC-6236 — Pan-RAS molecular glue in clinical development
KRAS inhibitors — KRAS-selective small molecule inhibitors approved or late-stage
Other RAS pathway inhibitors — MEK, ERK, and other MAPK pathway targeting approaches
Recent Developments
(January 2026) Completed upsized public offering of $225 million to fund pipeline advancement
(January 2026) Reported positive early Phase 1 data for ERAS-0015 showing confirmed partial responses and favorable safety profile
(January 2026) Updated 2026-2027 milestones with initial monotherapy data expected in H1 2026 for ERAS-0015
Open the full interactive Erasca, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.